Longevinix doesn't contain emodin. It is a blend of resveratrol, quercetin and IP6. This is the brand that the U of Wisconsin researcher interviewed on 60 Minutes was giving mice. On a Longevinex commercial (google) he says it seems like there is a synergy among the three compounds. Longevinex is micronized and someone posted on another thread that it is now 86%, not 50%, but I don't know.
I think in your case because your dog is small, I'd stick with Longevinex or find out how much of the three to give buy separately and mix in order to save money. (I assume mixing the three would be as effective, but I don't know that for sure.)
I think if I had a larger dog with cancer I'd give the first 500mg or so in Longevinex and if you wanted to give a full gram or more, add 500mg (or more) of 98% resv.
Quite right, Long. switched to 98% pure resveratrol in their caps months ago: little or no emodin. But we do not know how ferulic acid in the product will specifically affect canines, though we have reason to believe it should be avoided: ferulic acid augments angiogenesis, which would stimulate tumor growth.
Nutr Biochem. 2009 May 12. [Epub ahead of print]
Ferulic acid augments angiogenesis via VEGF, PDGF and HIF-1alpha.
Lin CM, Chiu JH, Wu IH, Wang BW, Pan CM, Chen YH.
Department of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; College of Medicine, Taipei Medical University, Taipei, Taiwan; Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Therapeutic angiogenesis is critical to wound healing and ischemic diseases such as myocardial infarction and stroke. For development of therapeutic agents, a search for new angiogenic agents is the key. Ferulic acid, a phytochemical found in many fruits and vegetables, exhibits a broad range of therapeutic effects on human diseases, including diabetes and cancer. This study investigated the augmenting effect of ferulic acid on angiogenesis through functional modulation of endothelial cells. Through endothelial cell migration and tube formation assays, ferulic acid (10(-6)-10(-4) M) was found to induce significant angiogenesis in human umbilical vein endothelial cells (HUVECs) in vitro without cytotoxicity. With chorioallantoic membrane assay, ferulic acid (10(-6)-10(-5) M) was also found to promote neovascularization in vivo. Using Western blot analysis and quantitative real-time polymerase chain reaction, we found that ferulic acid increased vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) expression in HUVECs. Furthermore, the amounts of hypoxic-induced factor (HIF) 1alpha mRNA and protein, the major regulator of VEGF and PDGF, also showed up-regulation by ferulic acid. Electrophoretic migration shift assay showed that the binding activity of HIF-1alpha was also enhanced with ferulic acid treatment of HUVECs. Moreover, inhibitors of extracellular-signal-regulated kinase 1/2 and phosphoinositide-3 kinase (PI3K) abolished the binding activity of HIF-1alpha and the subsequent activation of VEGF and PDGF production by ferulic acid. Thus, both mitogen-activated protein kinase and PI3K pathways were involved in the angiogenic effects of ferulic acid. Taken together, ferulic acid serves as an angiogenic agent to augment angiogenesis both in vitro and in vivo. This effect might be observed through the modulation of VEGF, PDGF and HIF-1alpha.
PMID: 19443196
Better, I think, to stick to 98% resveratrol for most cancers. It should be odorless and tasteless enough to mix with a food your beast likes.
However, with kidney failure I do not know if resveratrol will help. It has been beneficial in a rat model of kidney failure, and so might well help:
Ren Fail. 2006;28(2):161-9.
Protective effect of resveratrol, a polyphenolic phytoalexin on glycerol-induced acute renal failure in rat kidney.
Chander V, Chopra K.
Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. chandervikas2004@yahoo.co.uk
Rhabdomyolysis-induced myoglobinuric acute renal failure (ARF) accounts for about 10% to 40% of all cases of ARF. Reactive oxygen intermediates have been demonstrated to play an etiologic role in myoglobinuric renal failure. This study was designed to investigate the effect of resveratrol, a polyphenolic phytoalexin in glycerol-induced ARF in rats. Seven groups of rats were employed in this study, group I served as control; group II was given 50% glycerol (8 mL/kg, intramuscularly); groups III IV, and V were given glycerol plus resveratrol (2 mg/kg, 5 mg/kg, and 10 mg/kg p.o. route, respectively) 60 min prior to the glycerol injection; group VI received L-NAME (10 mg/kg, i.p.) along with glycerol and resveratrol (5 mg/kg), group VII animals received L-NAME (10 mg/kg) 30 min prior to glycerol administration. Renal injury was assessed by measuring plasma creatinine, blood urea nitrogen, creatinine, and urea clearance. The oxidative stress was measured by renal malondialdehyde levels and reduced glutathione levels, and by enzymatic activity of catalase, glutathione reductase, and superoxide dismutase. Tissue and urine nitrite levels were measured as an index of total nitric oxide levels. Glycero treatment resulted in a marked decrease in tissue and urine nitric oxide levels, renal oxidative stress, and significantly deranged the renal functions along with deterioration of renal morphology. Pre treatment of animals with resveratrol (5 and 10 mg/kg) 60 min prior to glycerol injection markedly attenuated the fall in nitric oxide levels, renal dysfunction, morphologic alterations, reduced elevated thiobarbituric acid reacting substances, and restored the depleted renal antioxidant enzymes. This protection afforded by resveratrol was significantly reversed by cotreatment of L-NAME along with resveratrol, clearly indicating that resveratrol exerts its protective effect through nitric oxide release along with the antioxidative effect in glycerol-induced ARF.
PMID: 16538975
Edited by maxwatt, 10 July 2009 - 02:27 AM.